News und Analysen
Here Are the Big Pharma Stocks to Own Based on R&D Spending
Just because a big pharma company is successful today doesn't mean it will be successful in a few years. Even the biggest blockbuster drugs eventually lose patent exclusivity or face new and....
3 Biotech Stocks That Could Soar in September
Winter seems to always be coming in Game of Thrones, but here in the real world, autumn is on the way. While the leaves will start falling in September, some biotech stocks could be set to....
Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story....
Is the System Rigged Against Biosimilars?
If you think prescription drug costs are high now, imagine what costs would be without generic drugs. Roughly 25% of total prescription drug sales in 2016 were generics. But it's a different story....
3 States Where Obamacare Premiums May Rise More Than 50% in 2018
Despite President Trump having been in office for more than seven months now and Republicans retaining control of both houses of Congress, the Affordable Care Act, which is best known as....
Better Buy: Welltower Inc. vs. Universal Health Services, Inc.
America is getting older, and the demographic shift is driving up demand for healthcare facilities and services. This long-term trend should supply the nursing homes in Welltower Inc.'s (NYSE:....
Say What? 2 New Studies Find Little Evidence That Marijuana Helps Treat Chronic Pain and PTSD
When it comes to growth industries, essentially nothing tops legal marijuana. According to cannabis research firm ArcView, the legal cannabis market in North America is slated to grow from $6.9....
3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
Illumina (NASDAQ: ILMN) has been -- and still is -- a leader in one of the most important scientific advances in human history. The company's technology helped usher in widespread use of gene....
3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
Illumina (NASDAQ: ILMN) has been -- and still is -- a leader in one of the most important scientific advances in human history. The company's technology helped usher in widespread use of gene....
3 Reasons Exact Sciences Is a Better Growth Stock Than Illumina
Illumina (NASDAQ: ILMN) has been -- and still is -- a leader in one of the most important scientific advances in human history. The company's technology helped usher in widespread use of gene....
Why Adamas Pharmaceuticals Inc Stock Skyrocketed Today
Shares of Adamas Pharmaceuticals (NASDAQ: ADMS) have skyrocketed today, up 42.3% as of 12:02 p.m. EDT, after the company announced yesterday evening that the Food and Drug Administration approved....
3 Top Healthcare Stocks to Buy Now
It's been a good year for healthcare stocks in general, but a handful of quality companies haven't been swept upward with the rest of the sector. Allergan plc (NYSE: AGN) and CVS Health Corp.....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
70 or Older? 3 Stocks You Should Consider Buying
Investment priorities naturally evolve as we age. For investors in their 70s, stability and income should be prioritized over growth and capital appreciation potential. That's why companies like....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
4 of the Highest-Growth Stocks in Biotech Today
Investing in the biotech industry can be a risky business. In most instances, the deck is stacked against a company succeeding. The vast majority of preclinical studies will fail to reach human....
Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today
Major benchmarks trended downward Wednesday, taking a break from the rally that had boosted stocks in the previous session. Investors seemed uncertain about President Donald Trump's plans to....
Why Ultragenyx Pharmaceutical Stock Is Sinking Today
Shares of the rare-disease drugmaker Ultragenyx Pharmaceutical (NASDAQ: RARE) are under pressure today after the company announced that its late-stage study assessing aceneuramic acid extended....
Here's Why Paratek Pharmaceuticals Soared as Much as 37% Today
Shares of clinical-stage biopharma Paratek Pharmaceuticals (NASDAQ: PRTK) soared 37% today after news leaked that the company is considering a sale.The stock has returned solid gains to investors....
2 Marijuana Stocks That Have Imploded Since August Began
In many ways, the legal marijuana industry could be described as the greatest thing since sliced bread for investors. Over the trailing one-year period, the average marijuana stock has increased....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....
3 Reasons AbbVie Is a Better Dividend Stock Than Gilead Sciences
Gilead Sciences (NASDAQ: GILD) claims one of the top-selling drugs in the world with Harvoni. But AbbVie (NYSE: ABBV) markets the best-selling drug in the world -- Humira. Gilead Sciences is one....
How Johnson & Johnson Makes Most of Its Money
As you might expect, Johnson & Johnson (NYSE: JNJ) makes a lot of money. Last year, the healthcare giant generated revenue totaling nearly $72 billion. Over the past decade, J&J raked in....